Zacks Investment Research
16 Jul 2026, 15:45 UTC · 13w ago
Verdict
Headline takes no side. We score PFE −0.80 across four claims — strongly bearish.
−0.80strongly bearish
More negative than 85% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
What the story claims
4 claims · scored −1 bearish … +1 bullish
Pfizer faces a significant patent cliff from 2026 to 2030, with key products including Eliquis and Ibrance losing exclusivity.
So whatLoss of exclusivity on core products creates a structural revenue gap that is difficult to offset and threatens long-term valuation.
More negative than 99% of claims this week
Pfizer's COVID-related revenues are projected to decline further to approximately $5 billion in 2026 from $6.7 billion in 2025.
Continue reading
5 related stories
More negative than 94% of claims this week
The loss of exclusivity cliff is expected to specifically reduce sales by approximately $1.5 billion in 2026.
More negative than 90% of claims this week
Pfizer's stock has been trading below both its 50-day and 200-day simple moving averages since mid-June.
More negative than 76% of claims this week
Which stocks this story touches
More negative than 85% of ticker scores this week
The company is facing declining COVID-related revenues, trading below key moving averages, and a significant upcoming patent cliff.
More positive than 6% of relationship scores this week
[mutual] Listed together as pharmaceutical companies in a comparative context.
More positive than 6% of relationship scores this week
[mutual] Listed together as pharmaceutical companies in a comparative context.
More positive than 6% of relationship scores this week
[mutual] Listed together as pharmaceutical companies in a comparative context.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1h ago
—
No price for PFE right now — the quote feed didn't answer.
PFE chart →
